<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006786.pub2" GROUP_ID="PREG" ID="444906111010364311" MERGED_FROM="" MODIFIED="2012-05-16 10:52:10 +0100" MODIFIED_BY="Denise Atherton" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.2.8&lt;/p&gt;" NOTES_MODIFIED="2009-08-11 16:26:30 +0100" NOTES_MODIFIED_BY="Sonja L  Henderson" REVIEW_NO="0527" REVMAN_SUB_VERSION="5.0.21" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2012-05-16 10:52:10 +0100" MODIFIED_BY="Denise Atherton">
<TITLE>Interventions for treating painful sickle cell crisis during pregnancy</TITLE>
<CONTACT MODIFIED="2012-05-16 10:52:10 +0100" MODIFIED_BY="Denise Atherton"><PERSON ID="0B71502082E26AA2005EBC6E010990A2" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Arturo</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Martí-Carvajal</LAST_NAME><SUFFIX>MD, MSc</SUFFIX><EMAIL_1>arturo.marti.carvajal@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Facultad de Ciencias de la Salud Eugenio Espejo</DEPARTMENT><ORGANISATION>Universidad Tecnológica Equinoccial</ORGANISATION><CITY>Quito</CITY><COUNTRY CODE="EC">Ecuador</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-05-16 10:52:10 +0100" MODIFIED_BY="Denise Atherton"><PERSON ID="0B71502082E26AA2005EBC6E010990A2" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Arturo</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Martí-Carvajal</LAST_NAME><SUFFIX>MD, MSc</SUFFIX><EMAIL_1>arturo.marti.carvajal@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Facultad de Ciencias de la Salud Eugenio Espejo</DEPARTMENT><ORGANISATION>Universidad Tecnológica Equinoccial</ORGANISATION><CITY>Quito</CITY><COUNTRY CODE="EC">Ecuador</COUNTRY></ADDRESS></PERSON><PERSON ID="EA9D288282E26AA20126CDD196C9A1E6" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Guiomar</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Peña-Martí</LAST_NAME><POSITION>Profesor Titular</POSITION><EMAIL_1>gpena@uc.edu.ve</EMAIL_1><EMAIL_2>guiomarhelena@cantv.net</EMAIL_2><ADDRESS><DEPARTMENT>Departamento de Obstetricia y Ginecología</DEPARTMENT><ORGANISATION>Universidad de Carabobo</ORGANISATION><ADDRESS_1>La Esmeralda, calle 160, D10-7,  San Diego</ADDRESS_1><CITY>Valencia</CITY><ZIP>2006</ZIP><REGION>Estado Carabobo</REGION><COUNTRY CODE="VE">Venezuela</COUNTRY><PHONE_1>+58 241 8712883</PHONE_1><PHONE_2>+58 241 8351587</PHONE_2><FAX_1>+58 241 8712883</FAX_1></ADDRESS></PERSON><PERSON ID="17710" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Gabriella</FIRST_NAME><LAST_NAME>Comunián-Carrasco</LAST_NAME><POSITION>Specialist in Obstetrics and Gynecology</POSITION><EMAIL_1>comunian@cantv.net</EMAIL_1><ADDRESS><DEPARTMENT>Departamento de Obstetricia y Ginecología</DEPARTMENT><ORGANISATION>Universidad de Carabobo</ORGANISATION><ADDRESS_1>Urbanización Fundación Mendoza calle 19</ADDRESS_1><ADDRESS_2>5ta etapa N° 22-40</ADDRESS_2><CITY>Valencia</CITY><ZIP>2001</ZIP><REGION>Estado Carabobo</REGION><COUNTRY CODE="VE">Venezuela</COUNTRY><PHONE_1>+58 241 8478492</PHONE_1><FAX_1>+58 241 8478492</FAX_1></ADDRESS></PERSON><PERSON ID="128C757782E26AA20114382D1BADDF46" ROLE="AUTHOR"><PREFIX>Dr.</PREFIX><FIRST_NAME>Arturo</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Martí-Peña</LAST_NAME><POSITION>Residencia "Los Sauces", Torre B</POSITION><EMAIL_1>ajmarti23@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Piso 3, # 34-B</DEPARTMENT><ORGANISATION>Urb. Los Sauces</ORGANISATION><ADDRESS_1>Ave. Bolívar Norte</ADDRESS_1><CITY>Valencia</CITY><REGION>Estado Carabobo</REGION><COUNTRY CODE="VE">Venezuela</COUNTRY><PHONE_1>+58  241 8216052</PHONE_1><FAX_1>+58 241 8712883</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-04-27 17:07:08 +0100" MODIFIED_BY="Arturo Martí-Carvajal">
<UP_TO_DATE>
<DATE DAY="20" MONTH="12" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="20" MONTH="12" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="12" MONTH="1" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2009"/>
</DATES>
<WHATS_NEW MODIFIED="2012-05-16 10:52:10 +0100" MODIFIED_BY="Denise Atherton"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-05-16 10:52:10 +0100" MODIFIED_BY="Denise Atherton"><DATE DAY="16" MONTH="5" YEAR="2012"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>


</WHATS_NEW>
<HISTORY MODIFIED="2012-05-16 10:52:10 +0100" MODIFIED_BY="Denise Atherton"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-05-16 10:52:10 +0100" MODIFIED_BY="Denise Atherton">
<DATE DAY="11" MONTH="8" YEAR="2009"/>
<DESCRIPTION>
<P>Declarations of interest updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2012-05-16 10:52:10 +0100" MODIFIED_BY="Denise Atherton">
<DATE DAY="11" MONTH="8" YEAR="2009"/>
<DESCRIPTION>
<P>Feedback from Keith Quirolo added and reply from authors added. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-08-11 13:40:02 +0100" MODIFIED_BY="Sonja L  Henderson">
<DATE DAY="9" MONTH="1" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2008-10-24 16:37:11 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2008-10-24 16:37:11 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2008-09-03 17:34:05 +0100" MODIFIED_BY="[Empty name]">
<NAME>Universidad de Carabobo</NAME>
<COUNTRY CODE="VE">Venezuela</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Iberoamerican Cochrane Centre</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-08-11 16:18:20 +0100" MODIFIED_BY="Sonja L  Henderson">
<SUMMARY MODIFIED="2008-10-24 15:26:16 +0100" MODIFIED_BY="[Empty name]">
<TITLE>
<I>Interventions for treating painful sickle cell crisis during pregnancy</I>
</TITLE>
<SUMMARY_BODY MODIFIED="2008-10-24 15:26:16 +0100" MODIFIED_BY="[Empty name]">
<P>
<BR/>Evidence to establish the beneficial and harmful effects of interventions for treating painful sickle crisis during pregnancy is lacking.</P>
<P>Sickle cell disease covers a group of inherited (genetic) haemoglobin disorders that cause a defect in red blood cells. The disease has been declared by WHO as a major world health problem.</P>
<P>The changes in the red blood cells can lead to damaged and blocked blood vessels. The most frequent complication of sickle cell disease is a painful vaso-occlusive crisis. Treatment may involve the non-surgical intervention with packed red cell transfusion, fluid replacement therapy, analgesic drugs (nonsteroidal anti-inflammatory agents or opiates), oxygen therapy and steroids (prednisone, dexamethasone, or methylprednisolone). Pregnant women with sickle cell disease have an increased incidence of sickle cell crises. Their unborn infants are also at high risk of illness and death. The effectiveness and safety of the different treatments is, therefore, particularly important. For example, sickle cell disease can lead to severe placental damage, yet the opiate morphine constricts the blood vessels in the placenta and so may harmful to the fetus.</P>
<P>The review authors searched the medical literature for randomised controlled trials in which non-surgical approaches were compared for their efficacy and safety. They could not find any randomised clinical trials on non-surgical interventions for the treatment of painful sickle cell crisis during pregnancy. Pregnant women were excluded from clinical trials studying opiate or non-opiate analgesics for treating painful sickle cell crisis.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-10-24 15:21:15 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2008-03-12 11:18:03 +0000" MODIFIED_BY="Denise Atherton">
<P>Sickle cell disease is a group of genetic haemoglobin disorders. All over the world, about 300,000 children with these disorders are born each year. Acute sickle cell pain episodes are the most common cause of hospitalisation. Pregnancy in women with sickle cell disease is associated with an increased incidence of maternal and fetal morbidity and mortality. The painful crisis is a severe complication of this illness, and it requires several interventions: packed red cell transfusion, fluid replacement therapy, analgesic drugs, oxygen therapy and steroids; but the approach is not standardised.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effectiveness and safety of different regimens of packed red cell transfusion, oxygen therapy, fluid replacement therapy, analgesic drugs, and steroids for the treatment of painful sickle cell crisis during pregnancy. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-10-24 15:21:15 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (December 2007), the Cochrane Cystic Fibrosis and Genetic Disorders Group's Trials Register (October 2007), <I>LILACS</I> database (1982 to December 2007) and the following web sites: ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</A>) (December 5, 2007); Current Controlled Trials (<A HREF="http://controlled-trials.com/">http://controlled-trials.com/</A>) (December 5, 2007), and Sistema de Información Esencial en Terapéutica y Salud (http://www.icf.uab.es/informacion/Papyrus/sietes.asp) (December 1, 2007). We also handsearched the European Haematology Association conference (June 2007), the American Society of Hematology conference (December 2007) and reference lists of all retrieved articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>We intended to include randomised clinical trials. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>We intended to summarise data by standard Cochrane Collaboration methodologies. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>We could not find any randomised clinical trials on interventions (packed red cell transfusion, oxygen therapy, fluid replacement therapy, analgesic drugs, and steroids) for the treatment of painful sickle cell crisis during pregnancy. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>This review found no randomised clinical trials on the safety and efficacy of interventions for treating painful sickle cell crisis during pregnancy. The effects of interventions need to be tested in randomised clinical trials. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-10-24 15:22:53 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-10-17 08:52:20 +0100" MODIFIED_BY="[Empty name]">
<P>Sickle cell disease (SCD) is a group of genetic haemoglobin disorders - abnormal structure of the haemoglobin - (<LINK REF="REF-Bunn-1997" TYPE="REFERENCE">Bunn 1997</LINK>; <LINK REF="REF-Pauling-1949" TYPE="REFERENCE">Pauling 1949</LINK>; <LINK REF="REF-Serjeant-2001" TYPE="REFERENCE">Serjeant 2001</LINK>) which have their origins in sub-Saharan Africa and the Indian sub-continent (<LINK REF="REF-Stuart-2004" TYPE="REFERENCE">Stuart 2004</LINK>; <LINK REF="REF-Weatherall-2006" TYPE="REFERENCE">Weatherall 2006</LINK>). The term SCD includes sickle cell anaemia (Hb SS); haemoglobin S combined with haemoglobin C (Hb SC); haemoglobin S associated with ß Thalassemia (Sß0 Thal and Sß+ Thal) and other double heterozygous conditions which cause clinical disease (<LINK REF="REF-Saunthararajah-2004" TYPE="REFERENCE">Saunthararajah 2004</LINK>; <LINK REF="REF-Serjeant-2001" TYPE="REFERENCE">Serjeant 2001</LINK>; <LINK REF="REF-Weatherall-2006" TYPE="REFERENCE">Weatherall 2006</LINK>). Haemoglobin S combined with normal haemoglobin (A), known as sickle trait (AS), is asymptomatic and therefore not part of this review. Population mobility has spread haemoglobin disorders through Europe, Asia, and the Americas. It means that millions of people have SCD worldwide. In Africa, the number of newborns affected by SCD is estimated at 200,000 per year (<LINK REF="REF-Diallo-2002" TYPE="REFERENCE">Diallo 2002</LINK>); all over the world, about 300,000 children with SCD are born each year (<LINK REF="REF-Serjeant-1997" TYPE="REFERENCE">Serjeant 1997</LINK>). SCD is a major health problem (<LINK REF="REF-WHO-2006" TYPE="REFERENCE">WHO 2006</LINK>).</P>
<P>Recently, the pathophysiology of SCD has been reviewed (<LINK REF="REF-Hebbel-2004" TYPE="REFERENCE">Hebbel 2004</LINK>; <LINK REF="REF-Steinberg-2006" TYPE="REFERENCE">Steinberg 2006</LINK>; <LINK REF="REF-Stuart-2004" TYPE="REFERENCE">Stuart 2004</LINK>; <LINK REF="REF-Weatherall-2006" TYPE="REFERENCE">Weatherall 2006</LINK>). Although SCD is primarily a defect of red blood cells (a haematological defect), changes in the red blood cells result in chronic vasculopathy (damage to blood vessels) (<LINK REF="REF-Hebbel-2004" TYPE="REFERENCE">Hebbel 2004</LINK>). It is mediated by a dysfunction of the nitric oxide (NO) biochemistry (<LINK REF="REF-Kato-2007" TYPE="REFERENCE">Kato 2007</LINK>; <LINK REF="REF-Mack-2006" TYPE="REFERENCE">Mack 2006</LINK>; <LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>).</P>
<P>The most frequent complication of SCD is vaso-occlusive or painful crises; this is a process of vascular obstruction in very small and, sometimes, large vessels that is initiated by sickle erythrocytes (<LINK REF="REF-Steinberg-2006" TYPE="REFERENCE">Steinberg 2006</LINK>). The remarkable symptom is severe or moderate bone pain, which indicates a haematological emergency. Acute sickle cell pain episodes are the most common cause of hospitalisation of patients with SCD (<LINK REF="REF-Ballas-2005" TYPE="REFERENCE">Ballas 2005</LINK>). Up to 58% of patients with SCD have been described with this complication (<LINK REF="REF-Babela-2005" TYPE="REFERENCE">Babela 2005</LINK>; <LINK REF="REF-Odum-2002" TYPE="REFERENCE">Odum 2002</LINK>).</P>
<P>In 1941, Kobak et al were pioneers in describing the complications associated with pregnancy and SCD (<LINK REF="REF-Kobak-1941" TYPE="REFERENCE">Kobak 1941</LINK>). Pregnancy in women with SCD is a high-risk situation (<LINK REF="REF-Rajab-2006" TYPE="REFERENCE">Rajab 2006</LINK>; <LINK REF="REF-Sun-2001" TYPE="REFERENCE">Sun 2001</LINK>). It is associated with increased incidence of maternal and fetal morbidity and mortality (<LINK REF="REF-Adam-1996" TYPE="REFERENCE">Adam 1996</LINK>; <LINK REF="REF-Leborgne_x002d_Samuel-2004" TYPE="REFERENCE">Leborgne-Samuel 2004</LINK>; <LINK REF="REF-Serjeant-2004" TYPE="REFERENCE">Serjeant 2004</LINK>; <LINK REF="REF-Villers-2008" TYPE="REFERENCE">Villers 2008</LINK>); however, in Hb SC females, pregnancy outcome is generally benign compared with SS disease (<LINK REF="REF-Serjeant-2005" TYPE="REFERENCE">Serjeant 2005</LINK>). Recently, the mechanisms of low birthweight in neonates of mothers with SS disease was reviewed (<LINK REF="REF-Thame-2007" TYPE="REFERENCE">Thame 2007</LINK>). Vaso-oclusive sickle cell crisis tends to occur more frequently during pregnancy (<LINK REF="REF-Adam-1996" TYPE="REFERENCE">Adam 1996</LINK>) and is the most common maternal complication in pregnancy associated with sickle haemoglobinopathies (<LINK REF="REF-Martin-1986" TYPE="REFERENCE">Martin 1986</LINK>). Up to 55.8% will have at least one painful episode during pregnancy (<LINK REF="REF-Powars-1986" TYPE="REFERENCE">Powars 1986</LINK>). The management of sickle cell crisis during pregnancy should be based on multidisciplinary management involving an obstetrician, a haematologist, an anaesthetist, and a haemoglobinopathy specialist nurse (<LINK REF="REF-Oteng_x002d_Ntim-2006" TYPE="REFERENCE">Oteng-Ntim 2006</LINK>).</P>
<P>The painful crisis in people with SCD could require several interventions: packed red cell transfusion, fluid replacement therapy, analgesic (Non steroidal anti-Inflammatory drugs -NSAID - and opioid or narcotic) drugs, oxygen therapy and steroids. However, their clinical effectiveness is unknown.</P>
<P>Morphine (opioid analgesic drug) is a vasoconstrictor of the placental vasculature (<LINK REF="REF-Kopecky-2000" TYPE="REFERENCE">Kopecky 2000</LINK>), and SS disease is associated with severe placental damage (<LINK REF="REF-Thame-2007" TYPE="REFERENCE">Thame 2007</LINK>); therefore, this combination could be deleterious for the fetus. There is no evidence for supporting morphine use for painful crises in SCD during pregnancy; however, this drug appeared at the top of a list of therapies for this medical condition (<LINK REF="REF-Chamberlain-1991" TYPE="REFERENCE">Chamberlain 1991</LINK>). Furthermore, opiates administration, both orally and parenterally by intravenous, intramuscular, or subcutaneous routes, has been recommended (<LINK REF="REF-ACOG-2007" TYPE="REFERENCE">ACOG 2007</LINK>; <LINK REF="REF-Kondylis-1998" TYPE="REFERENCE">Kondylis 1998</LINK>). However, pregnant women are excluded from clinical trials studying opiate or non-opiate analgesics for treating painful sickle cell crisis (<LINK REF="REF-Finkel-2007" TYPE="REFERENCE">Finkel 2007</LINK>; <LINK REF="REF-Quinn-2007" TYPE="REFERENCE">Quinn 2007</LINK>; <LINK REF="REF-Shord-2007" TYPE="REFERENCE">Shord 2007</LINK>; <LINK REF="REF-van-Beers-2007" TYPE="REFERENCE">van Beers 2007</LINK>). Ongoing clinical trials performed in women with painful sickle cell crisis exclude pregnant women (<LINK REF="REF-Macias-2007" TYPE="REFERENCE">Macias 2007</LINK>; <LINK REF="REF-NIHCC-2007" TYPE="REFERENCE">NIHCC 2007</LINK>).</P>
<P>Because of the above-mentioned arguments, it may be appropriate to ask two questions. First, is it ethical to prescribe a drug to pregnant women when they have been excluded from trials of this drug? Secondly, why do physicians prescribe drugs during pregnancy for this medical emergency when pregnancy is an exclusion criterion for clinical trials addressing developed in sickle cell scope?</P>
<P>Therefore, the primary aim of this review will be to examine the evidence for the effectiveness of the interventions, including the safety of their use, for painful sickle cell crisis during pregnancy.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effectiveness and safety of different regimens of packed red cell transfusion, oxygen therapy, fluid replacement therapy, analgesic drugs, and steroids for the treatment of painful sickle cell crisis during pregnancy. </P>
</OBJECTIVES>
<METHODS MODIFIED="2008-10-24 15:22:53 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-10-17 08:52:24 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>We considered randomised clinical trials that compare interventions with any other treatment for sickle cell crisis in pregnant women, irrespective of their publication status (we considered trials published in abstract form or letters), language or country. We only considered quasi-randomised controlled trials to evaluate the adverse events. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-10-17 08:52:22 +0100" MODIFIED_BY="[Empty name]">
<P>Pregnant women with all types of sickle cell disease irrespective of age, or setting.</P>
<P>We excluded pregnant women with sickle trait.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-09-03 16:49:01 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised trials in which non-surgical approaches have been compared. Non-surgical treatment includes packed red cell transfusion, oxygen therapy, fluid replacement therapy, analgesia (nonsteroidal anti-inflammatory agents or opiates agents), and steroids (prednisone, dexamethasone, or methylprednisolone). The comparisons include each other, or with placebo, or standard care.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-10-17 08:52:24 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-10-17 08:52:23 +0100" MODIFIED_BY="[Empty name]">
<P>We chose outcome measures pertinent to the woman's experience of acute sickle pain (<LINK REF="REF-Dunlop-2006" TYPE="REFERENCE">Dunlop 2006</LINK>):</P>
<OL>
<LI>patient observer-rated pain intensity, pain relief, or both;</LI>
<LI>duration of pain (hours);</LI>
<LI>low birth weight;</LI>
<LI>preterm delivery;</LI>
<LI>perinatal death;</LI>
<LI>maternal death.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-10-17 08:52:24 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Number of days of analgesic use;</LI>
<LI>number of days off work;</LI>
<LI>normal daily activities;</LI>
<LI>numbers and type of analgesics used (e.g. opiates);</LI>
<LI>days in hospital and other measures of health resources used (e.g. intensive care);</LI>
<LI>obstetric management (e.g. induction of labour);</LI>
<LI>Apgar score.</LI>
</OL>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>We used the following definition of adverse events: "any untoward medical occurrence not necessarily having a causal relationship with the treatment, but having resulted in the discontinuation of treatment" (<LINK REF="REF-ICH_x002d_GCP-1997" TYPE="REFERENCE">ICH-GCP 1997</LINK>).</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-10-24 15:22:53 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2008-10-24 15:22:53 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register by contacting the Trials Search Co-ordinator (December 2007). </P>
<P>The Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register is maintained by the Trials Search Co-ordinator and contains trials identified from:</P>
<OL>
<LI>quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</LI>
<LI>monthly searches of MEDLINE;</LI>
<LI>handsearches of 30 journals and the proceedings of major conferences;</LI>
<LI>weekly current awareness search of a further 36 journals plus monthly BioMed Central email alerts.</LI>
</OL>
<P>Details of the search strategies for CENTRAL and MEDLINE, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the &#8216;Specialized Register&#8217; section within the editorial information about the Cochrane Pregnancy and Childbirth Group.</P>
<P>Trials identified through the searching activities described above are given a code (or codes) depending on the topic. The codes are linked to review topics. The Trials Search Co-ordinator searches the register for each review using these codes rather than keywords.</P>
<P>In addition, we searched the following, using the terms using the terms sickle cell AND pregnancy:</P>
<OL>
<LI>The Cochrane Cystic Fibrosis and Genetic Disorders Group's Trials Register (October 2007);</LI>
<LI>
<I>LILACS </I>database (1982 to December 5 2007);</LI>
<LI>ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</A>) (December 5, 2007);</LI>
<LI>Current Controlled Trials (http://controlled-trials.com/) (December 5, 2007);</LI>
<LI>Sistema de Información Esencial en Terapéutica y Salud (<A HREF="http://www.icf.uab.es/informacion/Papyrus/sietes.asp">http://www.icf.uab.es/informacion/Papyrus/sietes.asp</A>) (December 1, 2007).</LI>
</OL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-09-03 17:08:10 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the abstract books of two major conferences:</P>
<OL>
<LI>The European Haematology Association (June 2007);</LI>
<LI>The American Society of Hematology (December 2007).</LI>
</OL>
<P>We checked the reference lists of all the trials identified by the above methods.</P>
<P>We did not apply any language restrictions.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-03-13 16:28:00 +0000" MODIFIED_BY="Sonja Henderson">
<P>We planned to screen the results of our search strategy for potentially relevant trials, and independently assess them for inclusion or exclusion using a pre-designed eligibility form based on the inclusion criteria. We planned to resolve disagreements through discussion until a consensus was reached. We did not find any potentially relevant randomised trials. If we identify trials that meet our inclusion criteria in the future, we will adhere to the prespecified protocol described in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-10-17 08:52:29 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-10-17 08:52:29 +0100" MODIFIED_BY="[Empty name]">
<P>We identified seven potentially relevant references through the initial bibliographical searches. After manually checking the titles and abstracts, we regarded none of the papers as eligible for further evaluation, as they did not report on interventions for treating painful sickle cell crisis during pregnancy.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>No studies were included. </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>The searches did not identify any randomised trials eligible for inclusion in this systematic review. We could not identify any ongoing trials either. There were no quasi-randomised studies which we could use to assess harmful effects of interventions for treating painful sickle crisis during pregnancy. </P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-09-03 16:41:20 +0100" MODIFIED_BY="[Empty name]">
<P>We have been unable to identify any clinical trials addressing the efficacy and safety of treatment approaches for treating painful sickle crisis during pregnancy; an emergency in this population. This is surprising in light of the high number of pregnant women worldwide who suffer from the most common and severe complication of SCD (sickle cell disease), a public health problem all over the world (<LINK REF="REF-WHO-2006" TYPE="REFERENCE">WHO 2006</LINK>).</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-10-17 08:52:34 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2008-10-17 08:52:34 +0100" MODIFIED_BY="[Empty name]">
<P>We found no randomised clinical trials of non-surgical treatments including packed red cell transfusion, oxygen therapy, fluid replacement therapy, analgesia (non-steroidal anti-inflammatory agents or opiates agents), and steroids (prednisone, dexamethasone, or methylprednisolone) for treating painful sickle cell crisis during pregnancy for inclusion in this review. Therefore, it is not possible to determine whether any of those interventions is beneficially effective or harmful for treating pregnant women with painful sickle cell crisis.<BR/>
</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>This systematic review has identified the need for well-designed, adequately powered randomised clinical trials to assess the benefits and harms of non-surgical treatment as a way of treating the painful crisis in pregnant women with sickle cell disease. The trials regarding this issue should be reported according to the CONSORT statement (www.consort-statement.org) for improving the quality of reporting of efficacy and get better reports of harms in clinical research. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-10-17 08:53:13 +0100" MODIFIED_BY="[Empty name]">
<P>We thank the Iberoamerican Cochrane Centre, Barcelona, Spain, with special gratitude to Dr Xavier Bonfill, Mr Jordi Pardo, and Dr David Rigau. We thank Prof Zarko Alfirevic for improving the quality of this Cochrane review. We thank peer reviewers for their contribution to enhancing the quality of this Cochrane review.</P>
<P>As part of the pre-publication editorial process, this review has been commented on by four peers (an editor and three referees who are external to the editorial team) and the Group's Statistical Adviser.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-08-11 16:18:20 +0100" MODIFIED_BY="Sonja L  Henderson">
<P>In 2004 Arturo Martí-Carvajal was employed by Eli Lilly to run a four-hour workshop on 'How to critically appraise clinical trials on osteoporosis and how to teach this'. This activity was not related to his work with The Cochrane Collaboration or any Cochrane review. </P>
<P>In 2007 Arturo Martí-Carvajal was employed by Merck to run a four-hour workshop on 'How to critically appraise clinical trials and how to teach this'. This activity was not related to his work with The Cochrane Collaboration or any Cochrane review.</P>
<P>Guiomar E Peña-Martí, Gabriella Comunián-Carrasco, Arturo J Martí-Peña: None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-01-09 22:28:12 +0000" MODIFIED_BY="[Empty name]">
<P>Dr Arturo Marti-Carvajal wrote the first draft of the review with input from Dr Guiomar Peña-Martí, Dr Gabriella Comunián, and Dr Arturo Martí-Peña.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-04-27 17:42:57 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2009-04-27 17:42:57 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2009-04-27 17:42:57 +0100" MODIFIED_BY="[Empty name]"/>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-10-19 21:51:29 +0100" MODIFIED_BY="Lynn Hampson">
<ADDITIONAL_REFERENCES MODIFIED="2008-10-19 21:51:29 +0100" MODIFIED_BY="Lynn Hampson">
<REFERENCE ID="REF-ACOG-2007" NAME="ACOG 2007" TYPE="JOURNAL_ARTICLE">
<AU>ACOG Practice Bulletin</AU>
<TI>Hemoglobinopathies in pregnancy</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2007</YR>
<VL>109</VL>
<PG>229-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Adam-1996" NAME="Adam 1996" TYPE="JOURNAL_ARTICLE">
<AU>Adam S</AU>
<TI>Caring for the pregnant woman with sickle cell crisis</TI>
<SO>Professional Care of Mother and Child</SO>
<YR>1996</YR>
<VL>6</VL>
<PG>34-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Babela-2005" NAME="Babela 2005" TYPE="JOURNAL_ARTICLE">
<AU>Babela JR, Nzingoula S, Senga P</AU>
<TI>Sickle-cell crisis in the child and teenager in Brazzaville, Congo. A retrospective study of 587 cases</TI>
<SO>Bulletin de la Société de Pathologie Exotique</SO>
<YR>2005</YR>
<VL>98</VL>
<PG>365-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ballas-2005" NAME="Ballas 2005" TYPE="JOURNAL_ARTICLE">
<AU>Ballas SK, Lusardi M</AU>
<TI>Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance</TI>
<SO>American Journal of Hematology</SO>
<YR>2005</YR>
<VL>79</VL>
<PG>17-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bunn-1997" NAME="Bunn 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bunn HF</AU>
<TI>Pathogenesis and treatment of sickle cell disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>337</VL>
<PG>762-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chamberlain-1991" NAME="Chamberlain 1991" TYPE="JOURNAL_ARTICLE">
<AU>Chamberlain G</AU>
<TI>ABC of antenatal care. Medical problems in pregnancy--II</TI>
<SO>BMJ</SO>
<YR>1991</YR>
<VL>302</VL>
<NO>6788</NO>
<PG>1327-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Diallo-2002" NAME="Diallo 2002" TYPE="JOURNAL_ARTICLE">
<AU>Diallo D, Tchernia G</AU>
<TI>Sickle cell disease in Africa</TI>
<SO>Current Opinion in Hematology</SO>
<YR>2002</YR>
<VL>9</VL>
<PG>111-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dunlop-2006" NAME="Dunlop 2006" TYPE="COCHRANE_REVIEW">
<AU>Dunlop RJ, Bennett KCLB</AU>
<TI>Pain management for sickle cell disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD003350. DOI: 10.1002/14651858.CD003350.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Finkel-2007" MODIFIED="2008-01-29 15:12:25 +0000" MODIFIED_BY="Lynn Hampson" NAME="Finkel 2007" TYPE="OTHER">
<AU>Finkel JL</AU>
<TI>Assessment of opioid analgesia in sickle cell</TI>
<SO>www.controlled-trials.com/</SO>
<YR>(accessed 5 December 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hebbel-2004" NAME="Hebbel 2004" TYPE="JOURNAL_ARTICLE">
<AU>Hebbel RP, Osarogiagbon R, Kaul D</AU>
<TI>The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy</TI>
<SO>Microcirculation</SO>
<YR>2004</YR>
<VL>11</VL>
<PG>129-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" NAME="Higgins 2005" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]</TI>
<SO>In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley &amp; Sons, Ltd</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICH_x002d_GCP-1997" NAME="ICH-GCP 1997" TYPE="OTHER">
<AU>International Conference on Harmonisation Expert Working Group</AU>
<TI>International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice</TI>
<SO>www.ich.org/cache/compo/276-254-1.html</SO>
<YR>(accessed 12 January 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kato-2007" MODIFIED="2008-09-03 16:23:40 +0100" MODIFIED_BY="[Empty name]" NAME="Kato 2007" TYPE="JOURNAL_ARTICLE">
<AU>Kato GJ, Gladwin MT, Steinberg MH</AU>
<TI>Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes</TI>
<SO>Blood Reviews</SO>
<YR>2007</YR>
<VL>21</VL>
<PG>37-47</PG>
<IDENTIFIERS MODIFIED="2008-09-03 16:23:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-03 16:23:40 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17084951"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kobak-1941" NAME="Kobak 1941" TYPE="JOURNAL_ARTICLE">
<AU>Kobak AJ, Stein PJ, Daro AF</AU>
<TI>Sickle cell anemia in pregnancy: a review of the literature and report of six cases</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1941</YR>
<VL>41</VL>
<PG>811-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kondylis-1998" MODIFIED="2008-01-09 22:24:52 +0000" MODIFIED_BY="[Empty name]" NAME="Kondylis 1998" TYPE="JOURNAL_ARTICLE">
<AU>Kondylis-deBlois K, Feingold M</AU>
<TI>Sickle cell disease</TI>
<SO>Primary Care Update Obstetrics and Gynecology</SO>
<YR>1998</YR>
<VL>5</VL>
<PG>28-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kopecky-2000" NAME="Kopecky 2000" TYPE="JOURNAL_ARTICLE">
<AU>Kopecky EA, Ryan ML, Barrett JF, Seaward PG, Ryan G, Koren G et al</AU>
<TI>Fetal response to maternally administered morphine</TI>
<SO>American Journal Obstetrics and Gynecology</SO>
<YR>2000</YR>
<VL>183</VL>
<PG>424-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leborgne_x002d_Samuel-2004" NAME="Leborgne-Samuel 2004" TYPE="JOURNAL_ARTICLE">
<AU>Leborgne-Samuel Y, Kadhel P, Ryan C, Vendittelli F</AU>
<TI>Sickle cell disease and pregnancy</TI>
<SO>La Revue du Praticien</SO>
<YR>2004</YR>
<VL>54</VL>
<NO>14</NO>
<PG>1578-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Macias-2007" MODIFIED="2008-01-29 15:31:05 +0000" MODIFIED_BY="Lynn Hampson" NAME="Macias 2007" TYPE="OTHER">
<AU>Macias C</AU>
<TI>Steroid treatment for sickle cell pain crisis</TI>
<SO>www.controlled-trials.com/</SO>
<YR>(accessed 5 December 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mack-2006" MODIFIED="2008-10-19 21:50:29 +0100" MODIFIED_BY="Lynn Hampson" NAME="Mack 2006" TYPE="JOURNAL_ARTICLE">
<AU>Mack AK, Kato GJ</AU>
<TI>Sickle cell disease and nitric oxide: a paradigm shift?</TI>
<SO>International Journal of Biochemistry &amp; Cell Biology</SO>
<YR>2006</YR>
<VL>38</VL>
<PG>1237-42</PG>
<IDENTIFIERS MODIFIED="2008-09-03 16:29:23 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-03 16:29:23 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16517208"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Martin-1986" NAME="Martin 1986" TYPE="JOURNAL_ARTICLE">
<AU>Martin JN Jr, Martin RW, Morrison JC</AU>
<TI>Acute management of sickle cell crisis in pregnancy</TI>
<SO>Clinics in Perinatology</SO>
<YR>1986</YR>
<VL>13</VL>
<PG>853-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NIHCC-2007" MODIFIED="2008-01-29 15:30:53 +0000" MODIFIED_BY="Lynn Hampson" NAME="NIHCC 2007" TYPE="OTHER">
<AU>National Institutes of Health Clinical Center</AU>
<TI>Nitric oxide inhalation to treat sickle cell pain crises</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00094887</SO>
<YR>(accessed 5 December 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Odum-2002" NAME="Odum 2002" TYPE="JOURNAL_ARTICLE">
<AU>Odum CU, Anorlu RI, Dim SI, Oyekan TO</AU>
<TI>Pregnancy outcome in HbSS-sickle cell disease in Lagos, Nigeria</TI>
<SO>West African Journal of Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>19-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oteng_x002d_Ntim-2006" MODIFIED="2008-01-09 22:30:29 +0000" MODIFIED_BY="[Empty name]" NAME="Oteng-Ntim 2006" NOTES="&lt;p&gt;Volume 16, Issue 6, December 2006, Pages 353-360&lt;/p&gt;" NOTES_MODIFIED="2008-01-09 22:30:29 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Oteng-Ntim E, Cottee C, Bewley S, Anionwu EN</AU>
<TI>Sickle cell disease in pregnancy</TI>
<SO>Current Obstetrics and Gynaecology</SO>
<YR>2006</YR>
<VL>16</VL>
<PG>353-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pauling-1949" NAME="Pauling 1949" TYPE="JOURNAL_ARTICLE">
<AU>Pauling L, Itano HA, Singer SJ, Wells IC</AU>
<TI>Sickle cell anemia, a molecular disease</TI>
<SO>Science</SO>
<YR>1949</YR>
<VL>110</VL>
<PG>543-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Powars-1986" NAME="Powars 1986" TYPE="JOURNAL_ARTICLE">
<AU>Powars DR, Sandhu M, Niland-Weiss J, Johnson C, Bruce S, Manning PR</AU>
<TI>Pregnancy in sickle cell disease</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1986</YR>
<VL>67</VL>
<NO>2</NO>
<PG>217-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Quinn-2007" MODIFIED="2008-01-29 15:30:41 +0000" MODIFIED_BY="Lynn Hampson" NAME="Quinn 2007" TYPE="OTHER">
<AU>Quinn CT</AU>
<TI>Ketorolac versus ibuprofen to treat painful episodes of sickle cell disease</TI>
<SO>www.controlled-trials.com/</SO>
<YR>(accessed 5 December 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rajab-2006" NAME="Rajab 2006" TYPE="JOURNAL_ARTICLE">
<AU>Rajab KE, Issa AA, Mohammed AM, Ajami AA</AU>
<TI>Sickle cell disease and pregnancy in Bahrain</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>2006</YR>
<VL>93</VL>
<PG>171-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saunthararajah-2004" MODIFIED="2008-01-29 15:29:02 +0000" MODIFIED_BY="Lynn Hampson" NAME="Saunthararajah 2004" TYPE="BOOK_SECTION">
<AU>Saunthararajah Y, Vichinsky EP, Embury SH</AU>
<TI>Sickle cell disease</TI>
<SO>Hematology: basic principles and practice</SO>
<YR>2004</YR>
<ED>Hoffman R</ED>
<PB>Churchill Livingstone</PB>
<CY>Edinburgh</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Serjeant-1997" NAME="Serjeant 1997" TYPE="JOURNAL_ARTICLE">
<AU>Serjeant GR</AU>
<TI>Sickle cell disease</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<PG>725-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Serjeant-2001" NAME="Serjeant 2001" TYPE="JOURNAL_ARTICLE">
<AU>Serjeant GR</AU>
<TI>The emerging understanding of sickle cell disease</TI>
<SO>British Journal of Haematology</SO>
<YR>2001</YR>
<VL>112</VL>
<PG>3-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Serjeant-2004" NAME="Serjeant 2004" TYPE="JOURNAL_ARTICLE">
<AU>Serjeant GR, Loy LL, Crowther M, Hambleton IR, Thame M</AU>
<TI>Outcome of pregnancy in homozygous sickle cell disease</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2004</YR>
<VL>103</VL>
<PG>1278-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Serjeant-2005" NAME="Serjeant 2005" TYPE="JOURNAL_ARTICLE">
<AU>Serjeant GR, Hambleton I, Thame M</AU>
<TI>Fecundity and pregnancy outcome in a cohort with sickle cell-haemoglobin C disease followed from birth</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>2005</YR>
<VL>112</VL>
<PG>1308-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shord-2007" MODIFIED="2008-01-29 15:30:29 +0000" MODIFIED_BY="Lynn Hampson" NAME="Shord 2007" TYPE="OTHER">
<AU>Shord SS</AU>
<TI>Codeine in sickle cell disease</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT00174538</SO>
<YR>(accessed 5 December 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Steinberg-2006" NAME="Steinberg 2006" TYPE="JOURNAL_ARTICLE">
<AU>Steinberg MH</AU>
<TI>Pathophysiologically based drug treatment of sickle cell disease</TI>
<SO>Trends in Pharmacological Sciences</SO>
<YR>2006</YR>
<VL>27</VL>
<PG>204-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stuart-2004" NAME="Stuart 2004" TYPE="JOURNAL_ARTICLE">
<AU>Stuart MJ, Nagel RL</AU>
<TI>Sickle-cell disease</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>364</VL>
<PG>1343-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sun-2001" NAME="Sun 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sun PM, Wilburn W, Raynor BD, Jamieson D</AU>
<TI>Sickle cell disease in pregnancy: twenty years of experience at Grady Memorial Hospital, Atlanta, Georgia</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2001</YR>
<VL>184</VL>
<PG>1127-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thame-2007" MODIFIED="2008-10-19 21:51:14 +0100" MODIFIED_BY="Lynn Hampson" NAME="Thame 2007" TYPE="JOURNAL_ARTICLE">
<AU>Thame M, Lewis J, Trotman H, Hambleton I, Serjeant G</AU>
<TI>The mechanisms of low birth weight in infants of mothers with homozygous sickle cell disease</TI>
<SO>Pediatrics</SO>
<YR>2007</YR>
<VL>120</VL>
<NO>3</NO>
<PG>e686-e693</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Beers-2007" NAME="van Beers 2007" TYPE="JOURNAL_ARTICLE">
<AU>van Beers EJ, van Tuijn CF, Nieuwkerk PT, Friederich PW, Vranken JH, Biemond BJ</AU>
<TI>Patient-controlled analgesia versus continuous infusion of morphine during vaso-occlusive crisis in sickle cell disease, a randomized controlled trial</TI>
<SO>American Journal of Hematology</SO>
<YR>2007</YR>
<VL>82</VL>
<NO>11</NO>
<PG>955-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Villers-2008" MODIFIED="2008-10-19 21:51:29 +0100" MODIFIED_BY="Lynn Hampson" NAME="Villers 2008" TYPE="JOURNAL_ARTICLE">
<AU>Villers MS, Jamison MG, De Castro LM, James AH</AU>
<TI>Morbidity associated with sickle cell disease in pregnancy</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2008</YR>
<VL>199</VL>
<NO>2</NO>
<PG>125.e1-125.e5</PG>
<IDENTIFIERS MODIFIED="2008-09-03 16:16:06 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-03 16:16:06 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18533123"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Weatherall-2006" NAME="Weatherall 2006" TYPE="BOOK_SECTION">
<AU>Weatherall D, Akinyanju O, Fucharoen S, Olivieri N, Musgrove P</AU>
<TI>Inherited disorders of hemoglobin</TI>
<SO>Disease control priorities in developing countries</SO>
<YR>2006</YR>
<PG>663-80</PG>
<EN>2nd</EN>
<PB>The World Bank and Oxford University Press</PB>
<CY>Washington (DC)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2006" NAME="WHO 2006" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Sickle-cell anaemia</TI>
<SO>http://www.who.int/gb/ebwha/pdf_files/WHA59/A59_R20-en.pdf</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2008-09-03 16:34:09 +0100" MODIFIED_BY="[Empty name]" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood KC, Hsu LL, Gladwin MT</AU>
<TI>Sickle cell disease vasculopathy: a state of nitric oxide resistance</TI>
<SO>Free Radical Biology &amp; Medicine</SO>
<YR>2008</YR>
<VL>44</VL>
<PG>1506-28</PG>
<IDENTIFIERS MODIFIED="2008-09-03 16:33:44 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-03 16:33:44 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18261470"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zavala-2006" MODIFIED="2008-01-29 15:34:14 +0000" MODIFIED_BY="Lynn Hampson" NAME="Zavala 2006" TYPE="OTHER">
<AU>Zavala D, Martí A, Peña-Martí G, Comunián G</AU>
<TI>Sheet to enter data for performing a Cochrane review</TI>
<SO>Universidad de Carabobo, Valencia, Venezuela</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-04-27 17:42:57 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-04-27 17:42:57 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-04-27 17:42:57 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-04-27 17:42:57 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-04-27 17:42:42 +0100" MODIFIED_BY="[Empty name]"/>
<FIGURES/>
<FEEDBACK MODIFIED="2009-08-11 16:20:48 +0100" MODIFIED_BY="Sonja L  Henderson">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2009-08-11 16:20:48 +0100" MODIFIED_BY="Sonja L  Henderson" NO="1">
<TITLE MODIFIED="2009-08-11 13:43:29 +0100" MODIFIED_BY="Sonja L  Henderson">Quirolo</TITLE>
<DATE_SUBMITTED>
<DATE DAY="6" MONTH="5" YEAR="2009"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2009-08-11 13:44:07 +0100" MODIFIED_BY="Sonja L  Henderson">
<P>These studies are not mentioned in this review, leading me to believe that it is incomplete:</P>
<P>- Koshy M, Burd L, Wallace D, Moawad A, Baron J. Prophylactic red-cell transfusions in pregnant patients with sickle cell disease. A randomized cooperative study. N Engl J Med. 1988;319:1447-1452.</P>
<P>- Howard RJ, Tuck SM, Pearson TC. Pregnancy in sickle cell disease in the UK: results of a multicentre survey of the effect of prophylactic blood transfusion on maternal and fetal outcome. Br J Obstet Gynaecol. 1995;102:947-951.</P>
<P>(Feedback received from Keith Quirolo)</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2009-08-11 16:20:22 +0100" MODIFIED_BY="Sonja L  Henderson">
<P>The Koshy 1988 trial is a trial of <B>prophylactic</B> blood transfusions for pregnant women with sickle cell disease. The focus of our review is <B>treating </B>painful sickle cell crisis; therefore, this trial does not meet our inclusion criteria. The Howard 1995 report is also about prophylactic blood transfusions but is not a trial. It is a survey and therefore is not eligible for inclusion in this review either.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2009-08-11 16:20:48 +0100" MODIFIED_BY="Sonja L  Henderson">
<P>Arturo Martí-Carvajal.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2008-10-17 08:53:36 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-10-17 08:53:36 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-03-13 16:17:13 +0000" MODIFIED_BY="Sonja Henderson">Methods to be used</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-17 08:53:36 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Assessment of methodological quality</HEADING>
<P>The author will use a standard data extraction form (<LINK REF="REF-Zavala-2006" TYPE="REFERENCE">Zavala 2006</LINK>). We will independently extract the data and will systematically contact the authors of trials in order to obtain missing data where possible.</P>
<P>We will examine the adequacy of the methods used to generate the allocation sequence; the concealment of allocation; and the level of blinding (clinician, participant, or outcome assessor). For each trial the authors will classify the risk of bias as high, moderate, or low. Overall, we will consider trials to be at low risk of bias if allocation concealment and blinding of participants are adequate.</P>
<P>We will also evaluate the risk of attrition bias, as estimated by the percentage of participants lost to follow up. We will exclude studies with total attrition more than 30%, or where the difference between groups exceeds 10%, or both, from the meta-analysis, but include them in the review.</P>
<P>We intend to use the following definitions.</P>
<SUBSECTION>
<HEADING LEVEL="4">Generation of the allocation sequence</HEADING>
<P>Adequate, if the allocation sequence was generated by a computer or random-number table. We will consider drawing of lots, tossing of a coin, shuffling of cards, or throwing of dice adequate if a person who was not otherwise involved in the recruitment of participants performed the procedure. Unclear, if the trial was described as randomised, but the method used for the allocation sequence generation was not described. Inadequate, if dates, names, or admittance numbers were used for the allocation of participants. These studies are known as quasi-randomised and we will exclude them from the efficacy analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<UL>
<LI>Adequate, if the allocation of participants involved a central independent unit, on-site locked computer, numbered drug bottles, or containers of identical appearance prepared by an independent pharmacist or investigator, or if sealed, opaque envelopes were used.</LI>
<LI>Unclear, if the trial was described as randomised, but the method used to conceal the allocation was not described.</LI>
<LI>Inadequate, if the allocation sequence was known to the investigators who assigned participants or if the study was quasi-randomised.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding (or masking)</HEADING>
<P>Adequate, if the participants of the trial were blinded to the intervention. Unclear, if there is no information on blinding.Not performed, if the participants were not blinded to the intervention.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Follow up</HEADING>
<UL>
<LI>Adequate, if the numbers and reasons for dropouts and withdrawals in each group were described or if it was specified that there were no dropouts or withdrawals.</LI>
<LI>Unclear, if the trial gave the impression that there had been no dropouts or withdrawals, but this was not specifically stated.</LI>
<LI>Inadequate, if the number or reasons for dropouts and withdrawals were not described.</LI>
</UL>
<P>We plan to extract the relative risk for each outcome. For continuous outcomes, we plan to record either mean change from baseline for each group or mean post-treatment or intervention values and their standard deviation or standard error for each group. We also plan to calculate a pooled estimate of treatment effect by calculating the mean difference. If statistical information is missing (such as standard deviations), we will try to extract them from other relevant information in the paper, such as P-values and confidence intervals. We will also contact the first author of the paper for missing data. We will seek data on the number of participants by allocated treatment group, irrespective of compliance and whether or not the participant was later thought to be ineligible or otherwise excluded from treatment or follow up. If we are not able to do so, for each study we will record whether the results pertain to an intention-to-treat or to an available case analysis.</P>
<P>We will examine data for skewness using the means and standard deviations as described in the Cochrane Handbook of Systematic Reviews for Interventions (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>). If data are skewed, we will present log-transformed data.</P>
<P>We will quantify the impact of statistical heterogeneity using I<SUP>2</SUP>, which describes the percentage of total variation across studies that is due to heterogeneity rather than sampling error (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). If the identified studies are comparable enough, we will summarise their findings using a fixed-effects model. In the case of significant heterogeneity, we will devote further research to identifying possible causes of heterogeneity by exploring the impact of the participants' and study's characteristics.</P>
<P>We anticipate clinical heterogeneity in the effect of the intervention for the following participant characteristics: age, severity of painful crisis, type of disease, type of interventions and gestational age. We will explore these sources of heterogeneity in the assessment of each outcome by subgroup analyses comparing, for example, mild and severe disease; disease type (i.e. SS type versus SC type); country and within country; teenage pregnant women with non-teenage pregnant women; type of intervention and regimens.</P>
<P>We plan to conduct a sensitivity analysis by comparing the results of all studies to those of high methodological quality. We will also attempt to assess whether the review is subject to publication bias by using a funnel plot.</P>
</SUBSECTION>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>